FCMI
Foresite Capital Management IV Portfolio holdings
AUM
$124M
This Quarter Return
-15.5%
1 Year Return
-24.36%
3 Year Return
+1.86%
5 Year Return
+16.17%
10 Year Return
–
AUM
$149M
AUM Growth
+$149M
(-25%)
Cap. Flow
-$20.9M
Cap. Flow
% of AUM
-14.06%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
5
New
–
Increased
1
Reduced
–
Closed
1
Top Buys
| 1 |
Pharvaris
PHVS
|
$4.79M |
Top Sells
| 1 |
KNTE
Kinnate Biopharma Inc. Common Stock
KNTE
|
$25.7M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Pharvaris
PHVS
$1.39B
| $80.7M | 54.23% | 4,293,854 +255,012 | +6% | +$4.79M |
|
2
Kura Oncology
KURA
$686M
| $38.1M | 25.59% | 1,849,947 | – | – |
|
3
Syndax Pharmaceuticals
SNDX
$1.41B
| $18M | 12.07% | 875,000 | – | – |
|
4
Lyell Immunopharma
LYEL
$213M
| $12.1M | 8.11% | 8,325,000 | – | – |
|
|
KNTE
5
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
| – | – | -9,671,643 | Closed | -$25.7M |
|